Breast Cancer Treatment in Resource Constrained Countries: a Zimbabwean Perspective

  • Webster KadzatsaEmail author
  • Sandra Ndarukwa-Jambwa
Global Breast Cancer (AB Chagpar, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Global Breast Cancer


Purpose of Review

Breast cancer is becoming a significant burden to the healthcare system in Zimbabwe. The financial toxicity of breast cancer treatment is a significant problem for patients even in the developed world. This review looks at the management of breast cancer patients in Zimbabwe relating it to the other developed nations.

Recent Findings

Despite the tremendous progress made by science in the care of women with breast cancer over the past few decades, most of the women in Zimbabwe are yet to benefit from this progress. There is poor access to modern screening methods, quality chemotherapy drugs and reliable radiotherapy services and lack of evidence-based medicine derived from our own settings. Out-of-pocket payments for healthcare are still the major health-funding model, and it denies most women access to quality and appropriate healthcare services.


An increase in the number of medical specialists treating breast cancer over the past 10 years has resulted in a slight improvement in diagnostic and treatment capability of the country; however, resources for breast cancer management in Zimbabwe remain far from being adequate. Universal health coverage (UHC) if achieved through the drive to attain the 17 Sustainable Development Goals (SDGs) will improve care for breast cancer patients.


Breast cancer Financial toxicity External validity Chemotherapy Radiotherapy 


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Chokunonga E, Borok M, Chingonzoh T, Chirenje Z, Makunike-Mutasa R, Manangazira P, et al. Pattern of cancer in Zimbabwe in 2016. ZNCR. 2018:2018.Google Scholar
  2. 2.
    Kadzatsa W, Ndlovu N, Chokunonga E. The predicted increase in cancer cases in Africa by the year 2050: positive or negative news? [Internet]. [cited 2019 Mar 28]. Available from:
  3. 3.
    • Kalipeni E, Semu LL, Mbilizi MA. The brain drain of health care professionals from sub-Saharan Africa: a geographic perspective. Prog Dev Stud. 2012;12(2–3):153–71. (This paper discuss the extent and impact of brain drain to healthcare delivery in Africa).CrossRefGoogle Scholar
  4. 4.
    Mathew A. Global survey of clinical oncology workforce. J Glob Oncol. 2018;4(4):1–12. Scholar
  5. 5.
    •• Black E, Richmond R. Improving early detection of breast cancer in sub-Saharan Africa: why mammography may not be the way forward. Glob Health. 2019;15(1):3. (The paper discuss the role of old breast screening methods in the developing world where access to modern methods is poor).CrossRefGoogle Scholar
  6. 6.
    Manna S, Holz MK. Tamoxifen action in ER-negative breast cancer. Signal Transduct Insights. 2016;5:1–7. Scholar
  7. 7.
    Mushonga M. Biomarker in breast cancer: therapeutic approaches in receptor undefined breast cancer patients and the discordance between best practices based on hormone receptor status in patients treated at Parirenyatwa Radiotherapy Centre [Master of Medicine in Radiotherapy]. [Harare]: University of Zimbabwe; 2018.Google Scholar
  8. 8.
    Volders JH, Negenborn VL, Spronk PE, Krekel NMA, Schoonmade LJ, Meijer S, et al. Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes. Breast Cancer Res Treat. 2018;168(1):1–12. Scholar
  9. 9.
    Rodby KA, Danielson KK, Shay E, Robinson E, Benjamin M, Antony AK. Trends in breast reconstruction by ethnicity: an institutional review centered on the treatment of an urban population. Am Surg. 2016;82(6):497–504.Google Scholar
  10. 10.
    Kirby RM, Basit A, Manimaran N. Patient choice significantly affects mastectomy rates in the treatment of breast cancer. Int Semin Surg Oncol ISSO. 2008;5:20. Scholar
  11. 11.
    Yen TWF, Laud PW, Sparapani RA, Nattinger AB. Surgeon specialization and use of sentinel lymph node biopsy for breast cancer. JAMA Surg. 2014;149(2):185–92. Scholar
  12. 12.
    •• Zhan Q-H, Fu J-Q, Fu F-M, Zhang J, Wang C. Survival and time to initiation of adjuvant chemotherapy among breast cancer patients: a systematic review and meta-analysis. Oncotarget. 2017;9(2):2739–51. (This paper demonstrates the negative effects of delayed adjuvant treatment in breast cancer).Google Scholar
  13. 13.
    • Freitas AGQ, Weller M, Freitas AGQ, Weller M. Patient delays and system delays in breast cancer treatment in developed and developing countries. Ciênc Amp Saúde Coletiva. 2015;20(10):3177–89. (This paper analyze the cause of treatment delays in cancer treatment in both developed and developing countries).CrossRefGoogle Scholar
  14. 14.
    Sheppard VB, Isaacs C, Luta G, Willey SC, Boisvert M, Harper FWK, et al. Narrowing racial gaps in breast cancer chemotherapy initiation: the role of the patient-provider relationship. Breast Cancer Res Treat. 2013;139(1):207–16. Scholar
  15. 15.
    Mitchell J, Lannin DR, Mathews HF, Swanson MS. Religious beliefs and breast cancer screening. J Womens Health. 2002;11(10):907–15. Scholar
  16. 16.
    • Ndarukwa S, Nyakabau AM, Chagpar AB, Raben D, Ndlovu N, Kadzatsa W, et al. American Society of Clinical Oncology Multidisciplinary Cancer Management Course: connecting lives, cancer care, education, and compassion in Zimbabwe—a pilot for efforts of sustainable benefit? J Glob Oncol. 2016;3(4):409–17. (This paper discuss the role that ASCO is taking to improve cancer treatment worldwide).CrossRefGoogle Scholar
  17. 17.
    Tong CWS, Wu M, Cho WCS, To KKW. Recent advances in the treatment of breast cancer. Front Oncol [Internet]. 2018;8. Available from:,
  18. 18.
    Hamel LM, Penner LA, Albrecht TL, Heath E, Gwede CK, Eggly S. Barriers to clinical trial enrollment in racial and ethnic minority patients with cancer. Cancer Control J Moffitt Cancer Cent. 2016;23(4):327–37. Scholar
  19. 19.
    •• Mayor S. WHO includes 16 new cancer drugs on the list of essential medicines. Lancet Oncol. 2015;16(7):757. (This paper indicate the new drugs that were been added the basic chemotherapy required drugs for cancer treatment ).CrossRefGoogle Scholar
  20. 20.
    Sharrar RG, Dieck GS. Monitoring product safety in the postmarketing environment. Ther Adv Drug Saf. 2013;4(5):211–9. Scholar
  21. 21.
    •• Dyer O. Drugs exported from India to Africa are poorer quality than those sent elsewhere. BMJ. 2014;349:g6017. (This paper discusses the quality of drugs that patients in African get).CrossRefGoogle Scholar
  22. 22.
    Sambira. Counterfeit drugs raise Africa’s temperature | Africa Renewal [Internet]. 2013 [cited 2019 Mar 26]. Available from:
  23. 23.
    Venhuis BJ, Oostlander AE, Giorgio DD, Mosimann R, du Plessis I. Oncology drugs in the crosshairs of pharmaceutical crime. Lancet Oncol. 2018;19(4):e209–17. Scholar
  24. 24.
    Abdel-Wahab M, Bourque J-M, Pynda Y, Iżewska J, der Merwe DV, Zubizarreta E, et al. Status of radiotherapy resources in Africa: an International Atomic Energy Agency analysis. Lancet Oncol. 2013;14(4):e168–75. Scholar
  25. 25.
    • Bese NS, Sut PA, Ober A. The effect of treatment interruptions in the postoperative irradiation of breast cancer. Oncology. 2005;69(3):214–23. (This paper indicates the need of reliable radiotherapy services in improving the outcome of breast cancer patients on RT).CrossRefGoogle Scholar
  26. 26.
    Bradley JA, Mendenhall NP. Novel radiotherapy techniques for breast cancer. Annu Rev Med. 2018;69(1):277–88. Scholar
  27. 27.
    •• Omisore AG. Attaining Sustainable Development Goals in sub-Saharan Africa; the need to address environmental challenges. Environ Dev. 2018;25:138–45. (This paper indicates the need for a health funding mechanism that allow an increase equity in health care in the developing world).CrossRefGoogle Scholar
  28. 28.
    Russo G, Bloom G, McCoy D. Universal health coverage, economic slowdown and system resilience: Africa’s policy dilemma. BMJ Glob Health. 2017;2(3):e000400. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Radiotherapy and Oncology, College of Health SciencesUniversity of ZimbabweHarareZimbabwe
  2. 2.Radiotherapy Centre, Parirenyatwa Group of HospitalUniversity of ZimbabweHarareZimbabwe

Personalised recommendations